Nasdaq · CIK 0001798749
JBIO Jade Biosciences, Inc.
Insider trading from SEC Form 4. Last filing Feb 13, 2026. Close $14.39 on Oct 9, 2026, +61% from the 52-week low and -46% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
JBIOOct 9, 2026 · close 14.39
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Jade Biosciences, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 39Weak | Tom Frohlich Chief Executive Officer buy | $44k 6,000 shares | - | - |
Transactions
The last 18 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | Bradford D. Dahms Chief Financial Officer | AGrant or award Common Stock | +37,813 | $0.00 | $0 | 37,813 | Feb 13, 2026 |
| Feb 12, 2026 | Tom Frohlich Chief Executive Officer | AGrant or award Common Stock | +78,750 | $0.00 | $0 | 86,331 | Feb 13, 2026 |
| Feb 12, 2026 | Andrew James King See Remarks | AGrant or award Common Stock | +41,250 | $0.00 | $0 | 386,113 | Feb 13, 2026 |
| Feb 12, 2026 | Elizabeth Balta See Remarks | AGrant or award Common Stock | +28,125 | $0.00 | $0 | 28,125 | Feb 13, 2026 |
| Feb 12, 2026 | Elizabeth Balta See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +168,750 | $0.00 | $0 | 168,750 | Feb 13, 2026 |
| Feb 12, 2026 | Bradford D. Dahms Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +226,875 | $0.00 | $0 | 226,875 | Feb 13, 2026 |
| Feb 12, 2026 | Tom Frohlich Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +472,500 | $0.00 | $0 | 472,500 | Feb 13, 2026 |
| Feb 12, 2026 | Andrew James King See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +247,500 | $0.00 | $0 | 247,500 | Feb 13, 2026 |
| Oct 6, 2025 | Fairmount Funds Management LLC director, owner | AGrant or award Common Stockindirect: By Fairmount Healthcare Fund II L.P. | +1,333,126 | $9.14 | $12M | 1,897,677 | Oct 8, 2025 |
| Oct 6, 2025 | Fairmount Funds Management LLC director, owner | AGrant or award Pre-Funded Warrant (Right to Buy)derivativeindirect: By Fairmount Healthcare Fund II L.P. | +855,047 | $9.14 | $7.8M | 855,047 | Oct 8, 2025 |
| Jul 14, 2025 | Bradford D. Dahms Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +526,000 | $0.00 | $0 | 526,000 | Jul 14, 2025 |
| May 16, 2025 | Tom Frohlich Chief Executive Officer | POpen-market purchase Common Stock | +6,000 | $7.40 | $44k | 6,000 | May 19, 2025 |
| Apr 29, 2025 | Christopher W. Cain director | AGrant or award Stock Option (Right to Buy)derivative | +23,017 | $0.00 | $0 | 23,017 | May 1, 2025 |
| Apr 29, 2025 | Eric Dobmeier director | AGrant or award Stock Option (Right to Buy)derivative | +23,017 | $0.00 | $0 | 23,017 | May 1, 2025 |
| Apr 29, 2025 | Fairmount Funds Management LLC director, owner | AGrant or award Stock Option (Right to Buy)derivative | +23,017 | $0.00 | $0 | 23,017 | May 1, 2025 |
| Apr 29, 2025 | Lawrence Otto Klein director | AGrant or award Stock Option (Right to Buy)derivative | +23,017 | $0.00 | $0 | 23,017 | May 1, 2025 |
| Apr 29, 2025 | Erin Lavelle director | AGrant or award Stock Option (Right to Buy)derivative | +23,017 | $0.00 | $0 | 23,017 | May 1, 2025 |
| Apr 28, 2025 | Ra Capital Management, L.p. owner | JOther Common Stockindirect: See footnotes | +1,062,326 | - | - | 1,287,858 | Apr 30, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Elizabeth BaltaSee Remarks
- Christopher W. Caindirector
- Eric Dobmeierdirector
- Bradford D. DahmsChief Financial Officer
- Fairmount Funds Management LLCdirector, owner
- Tom FrohlichChief Executive Officer
- Andrew James KingSee Remarks
- Lawrence Otto Kleinceo, officer, director
- Erin Lavelledirector
- Ra Capital Management, L.p.owner, director
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.